OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signalingECCO'18 Vienna 2018
1
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST studyECCO'18 Vienna 2018
1
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)ECCO'18 Vienna 2018
1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II studyECCO'18 Vienna 2018
1
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS studyECCO'18 Vienna 2018
1
OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the eneida registryECCO'18 Vienna 2018
1
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populationsECCO'18 Vienna 2018
1
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort studyECCO'18 Vienna 2018
1
Pharmacoepidemiological studies on IBD using national registries. Examples from France4th EpiCom Workshop 2018
1